Difference between revisions of "Effect of development of health care system in emerging market countries to existing pharmaceutical industry"
Jump to navigation
Jump to search
| (One intermediate revision by the same user not shown) | |||
| Line 19: | Line 19: | ||
==Paradigms:== | ==Paradigms:== | ||
Well being vs. Treating the sick | |||
==Experts:== | ==Experts:== | ||
WHO | |||
==Timing:== | ==Timing:== | ||
Dates for key milestones in the development of the driving force. | Dates for key milestones in the development of the driving force. | ||
==Web Resources:== | ==Web Resources:== | ||
Useful resources on the web relating to this force. | Useful resources on the web relating to this force. | ||
Latest revision as of 20:09, 16 September 2009
This page is under construction and edited by Susan Liu EMBA09. In case of any questions/remarks, feel free to contact me
Description:
Generic durgs will be mainstream. Western pharmaceutical companies no longer can hold on to their patent with current business model.
Enablers:
WHO
India medical development
Inhibitors:
Giant pharmaceutical corporations in emgerging markets
De-globalization
Paradigms:
Well being vs. Treating the sick
Experts:
WHO
Timing:
Dates for key milestones in the development of the driving force.
Web Resources:
Useful resources on the web relating to this force.